COAG (Hemab Therapeutics Holdings) OCF Margin %: 0.00% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

COAG Hemab Therapeutics Holdings Inc COAG
11 GF Score
Price $46.54
! 2 Warning Signs
View Full Analysis

What is Hemab Therapeutics Holdings OCF Margin %?

Hemab Therapeutics Holdings COAG +3.48% 11 OCF Margin % is 0.00% as of Dec. 2025. GuruFocus rates COAG with a GF Score™ of 11/100. The stock has 2 warning signs investors should review. Among 953 Biotechnology companies, Hemab Therapeutics Holdings ranks worse than 104931.69% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Hemab Therapeutics Holdings's Cash Flow from Operations for the six months ended in Dec. 2025 was $-61.48 Mil. Hemab Therapeutics Holdings's Revenue for the six months ended in Dec. 2025 was $0.00 Mil. Therefore, Hemab Therapeutics Holdings's OCF Margin % for the quarter that ended in Dec. 2025 was 0.00%.

As of today, Hemab Therapeutics Holdings's current OCF Yield % is -2.83%.

The historical rank and industry rank for Hemab Therapeutics Holdings's OCF Margin % or its related term are showing as below:


COAG's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -64.23
* Ranked among companies with meaningful OCF Margin % only.

Hemab Therapeutics Holdings OCF Margin % Related Terms

Hemab Therapeutics Holdings OCF Margin % Historical Data

* Premium members only.

The historical data trend for Hemab Therapeutics Holdings's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hemab Therapeutics Holdings OCF Margin % Chart

Hemab Therapeutics Holdings Annual Data
Trend Dec24 Dec25
OCF Margin %
0.00 0.00

Hemab Therapeutics Holdings Semi-Annual Data
Dec24 Dec25
OCF Margin % 0.00 0.00
COAG
11GF Score
Hemab Therapeutics Holdings Inc COAG
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hemab Therapeutics Holdings OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Hemab Therapeutics Holdings's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-61.475/0
= %

Hemab Therapeutics Holdings's OCF Margin for the quarter that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-61.475/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Hemab Therapeutics Holdings (COAG) has a OCF Margin % of 0.00% as of Dec. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Hemab Therapeutics Holdings and its competitors. According to the industry distribution chart, Hemab Therapeutics Holdings ranks #999999 out of 953 companies in the Biotechnology industry.
Is Hemab Therapeutics Holdings' OCF Margin % too high?
Hemab Therapeutics Holdings' current OCF Margin % is 0.00%. Based on the distribution chart, Hemab Therapeutics Holdings ranks #999999 out of 953 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Hemab Therapeutics Holdings has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Hemab Therapeutics Holdings' OCF Margin % compare to ZLAB and SLS?
According to the Biotechnology industry distribution chart, Hemab Therapeutics Holdings ranks #999999 out of 953 companies for OCF Margin %. This places Hemab Therapeutics Holdings in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Hemab Therapeutics Holdings and its competitors. Hemab Therapeutics Holdings's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hemab Therapeutics Holdings stock overvalued right now?
Hemab Therapeutics Holdings (COAG) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Hemab Therapeutics Holdings' overall GF Score™ is 11/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Hemab Therapeutics Holdings (COAG), the current OCF Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Hemab Therapeutics Holdings Business Description

Address 101 Main Street, Suite 1220, Cambridge, MA, USA, 02142
Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.
11GF Score

Get the complete analysis for COAG

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$46.54
Price